NCT02673814View on ClinicalTrials.gov

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 29, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2018

Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

durvalumab

BIOLOGICAL

bavituximab

Sponsors
All Listed Sponsors
lead

Peregrine Pharmaceuticals

INDUSTRY